Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triamcinolone Acetonide + Conbercept for Refractory DME
NCT04627402Unknown
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Nov 2020
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised trial of triamcinolone acetonide in diabetic macular edema (DME) (2 arms), sponsored by Zhongshan Ophthalmic Center. Primary endpoint: Macular thickness at 24 weeks. Status: unknown.
02
Drugs
triamcinolone acetonide
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04627402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04627402.